MX2020002462A - Estratificacion de genotipo en tratamiento y prevencion de diabetes. - Google Patents

Estratificacion de genotipo en tratamiento y prevencion de diabetes.

Info

Publication number
MX2020002462A
MX2020002462A MX2020002462A MX2020002462A MX2020002462A MX 2020002462 A MX2020002462 A MX 2020002462A MX 2020002462 A MX2020002462 A MX 2020002462A MX 2020002462 A MX2020002462 A MX 2020002462A MX 2020002462 A MX2020002462 A MX 2020002462A
Authority
MX
Mexico
Prior art keywords
prevention
diabetes treatment
genotype
stratification
patient
Prior art date
Application number
MX2020002462A
Other languages
English (en)
Inventor
Anders Essen-Möller
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of MX2020002462A publication Critical patent/MX2020002462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a un método al tratamiento o la prevención de una enfermedad autoinmune en un paciente, que comprende: (a) determinar el genotipo de HLA del paciente, y (b) someter al paciente a un régimen de tratamiento sobre la base de dicho genotipo.
MX2020002462A 2017-09-08 2018-09-10 Estratificacion de genotipo en tratamiento y prevencion de diabetes. MX2020002462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1751094 2017-09-08
PCT/SE2018/050904 WO2019050465A1 (en) 2017-09-08 2018-09-10 STRATIFICATION OF GENOTYPE IN THE TREATMENT AND PREVENTION OF DIABETES

Publications (1)

Publication Number Publication Date
MX2020002462A true MX2020002462A (es) 2020-09-22

Family

ID=65634471

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002462A MX2020002462A (es) 2017-09-08 2018-09-10 Estratificacion de genotipo en tratamiento y prevencion de diabetes.

Country Status (20)

Country Link
US (1) US20210077587A1 (es)
EP (2) EP3954384A1 (es)
JP (2) JP7337780B2 (es)
KR (2) KR102607713B1 (es)
CN (1) CN111372602A (es)
CA (1) CA3074264A1 (es)
CY (1) CY1124881T1 (es)
DK (1) DK3678692T3 (es)
EA (1) EA202090673A1 (es)
ES (1) ES2902075T3 (es)
HR (1) HRP20211989T1 (es)
HU (1) HUE057216T2 (es)
IL (2) IL273016B2 (es)
LT (1) LT3678692T (es)
MX (1) MX2020002462A (es)
PL (1) PL3678692T3 (es)
PT (1) PT3678692T (es)
RS (1) RS62725B1 (es)
SI (1) SI3678692T1 (es)
WO (1) WO2019050465A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873601A4 (en) * 2019-05-14 2022-03-23 Provention Bio, Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI923719A0 (fi) * 1992-08-19 1992-08-19 Jaakko Tuomilehto Detektering av susceptibilitet foer diabetes.
EP1755631A2 (en) 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
KR20100022022A (ko) * 2007-04-24 2010-02-26 다이아미드 쎄라퓨틱스 아베 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
WO2015187087A2 (en) 2014-06-04 2015-12-10 Diamyd Medical Ab Novel combinations for antigen based therapy
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Also Published As

Publication number Publication date
JP7551848B2 (ja) 2024-09-17
WO2019050465A1 (en) 2019-03-14
KR20230167442A (ko) 2023-12-08
SI3678692T1 (sl) 2022-04-29
IL273016A (en) 2020-04-30
KR102607713B1 (ko) 2023-11-29
IL312528A (en) 2024-07-01
JP7337780B2 (ja) 2023-09-04
JP2020533306A (ja) 2020-11-19
CN111372602A (zh) 2020-07-03
US20210077587A1 (en) 2021-03-18
PT3678692T (pt) 2021-12-29
KR20200051737A (ko) 2020-05-13
RS62725B1 (sr) 2022-01-31
EP3954384A1 (en) 2022-02-16
EP3678692A1 (en) 2020-07-15
HRP20211989T1 (hr) 2022-03-18
EP3678692A4 (en) 2021-06-02
EP3678692B1 (en) 2021-10-20
LT3678692T (lt) 2022-01-10
EA202090673A1 (ru) 2020-06-23
HUE057216T2 (hu) 2022-04-28
ES2902075T3 (es) 2022-03-24
IL273016B2 (en) 2024-10-01
PL3678692T3 (pl) 2022-02-28
IL273016B1 (en) 2024-06-01
CA3074264A1 (en) 2019-03-14
DK3678692T3 (da) 2022-01-03
JP2023116726A (ja) 2023-08-22
CY1124881T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
MX2020002462A (es) Estratificacion de genotipo en tratamiento y prevencion de diabetes.
PH12018500515A1 (en) Therapeutic cd47 antibodies
MX2018002293A (es) Sistemas y métodos para las llamadas variantes de alta precisión.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2015128803A3 (en) System and method for auto-contouring in adaptive radiotherapy
GB2574997A (en) Multi-factor document analysis
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
MX2018006523A (es) Tecnicas para asignacion de asuntos.
MX2024001909A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
NZ767902A (en) Methods of treating ulcerative colitis
PL3183701T3 (pl) Klient, platforma obliczeniowa, oraz sposoby przeprowadzania bezpiecznych transakcji
EP3073368A8 (en) Human interface device input fusion
EP3347844A4 (en) METHOD AND SYSTEM FOR DIAGNOSIS OF DISEASES AND FOR THE PREPARATION OF TREATMENT RECOMMENDATIONS
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
TW201614507A (en) Methods and devices for finding settings to be used in relation to a sensor unit connected to a processing unit
EP3342864A4 (en) DIAGNOSTIC PROCEDURE FOR AUTOIMMUNE DISEASES, BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES AND ACTIVE AGGREGATE FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
PH12015502100A1 (en) Reducing the risk of autoimmune disease
MX363679B (es) Metodo para diagnosticar cancer.
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
GB201222554D0 (en) Diagnostic for determining skeletal health
TN2017000517A1 (en) MULTl-PEPTIDE COMPOSITION
MX2019001016A (es) Dispositivo de ensayo y metodo para la evaluacion de celulas sanguineas.